Quest Partners LLC Acquires Shares of 2,145 Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Quest Partners LLC acquired a new stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 2,145 shares of the biopharmaceutical company’s stock, valued at approximately $119,000.

Other institutional investors have also bought and sold shares of the company. nVerses Capital LLC bought a new stake in shares of Ultragenyx Pharmaceutical in the 2nd quarter worth about $33,000. UMB Bank n.a. lifted its holdings in shares of Ultragenyx Pharmaceutical by 58.1% in the 2nd quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 352 shares during the last quarter. Values First Advisors Inc. bought a new stake in shares of Ultragenyx Pharmaceutical in the 3rd quarter worth about $56,000. Capital Performance Advisors LLP bought a new stake in shares of Ultragenyx Pharmaceutical in the 3rd quarter worth about $107,000. Finally, KBC Group NV lifted its holdings in shares of Ultragenyx Pharmaceutical by 24.5% in the 3rd quarter. KBC Group NV now owns 2,568 shares of the biopharmaceutical company’s stock worth $143,000 after acquiring an additional 506 shares during the last quarter. Institutional investors own 97.67% of the company’s stock.

Analyst Upgrades and Downgrades

RARE has been the subject of several analyst reports. HC Wainwright raised their target price on shares of Ultragenyx Pharmaceutical from $82.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. TD Cowen raised their price target on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $121.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, November 12th. JPMorgan Chase & Co. reduced their price target on shares of Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating on the stock in a research note on Thursday, November 21st. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $77.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, November 6th. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $87.46.

Ultragenyx Pharmaceutical Stock Performance

NASDAQ RARE opened at $47.63 on Friday. The company has a market capitalization of $4.40 billion, a price-to-earnings ratio of -7.36 and a beta of 0.58. The company’s 50-day simple moving average is $52.04 and its two-hundred day simple moving average is $48.61. Ultragenyx Pharmaceutical Inc. has a one year low of $37.02 and a one year high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, beating analysts’ consensus estimates of ($1.45) by $0.05. The business had revenue of $139.49 million for the quarter, compared to the consensus estimate of $135.28 million. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. The company’s revenue for the quarter was up 42.3% on a year-over-year basis. During the same quarter last year, the firm posted ($2.23) EPS. Equities analysts expect that Ultragenyx Pharmaceutical Inc. will post -6.2 earnings per share for the current fiscal year.

Insider Transactions at Ultragenyx Pharmaceutical

In related news, CFO Howard Horn sold 7,465 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Thursday, October 10th. The shares were sold at an average price of $52.76, for a total value of $393,853.40. Following the completion of the sale, the chief financial officer now directly owns 92,301 shares in the company, valued at $4,869,800.76. This trade represents a 7.48 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Emil D. Kakkis sold 20,000 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $55.85, for a total transaction of $1,117,000.00. Following the completion of the sale, the chief executive officer now owns 2,223,985 shares of the company’s stock, valued at $124,209,562.25. This trade represents a 0.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 27,556 shares of company stock valued at $1,515,967 in the last 90 days. Insiders own 5.80% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.